hTERT Peptide Fragment GV1001 Prevents the Development of Porphyromonas gingivalis -Induced Periodontal Disease and Systemic Disorders in ApoE -Deficient Mice

GV1001, an anticancer vaccine, exhibits other biological functions, including anti-inflammatory and antioxidant activity. It also suppresses the development of ligature-induced periodontitis in mice. ( ), a major human oral bacterium implicated in the development of periodontitis, is associated with various systemic disorders, such as atherosclerosis and Alzheimer's disease (AD). This study aimed to explore the protective effects of GV1001 against -induced periodontal disease, atherosclerosis, and AD-like conditions in ( )-deficient mice. GV1001 effectively mitigated the development of -induced periodontal disease, atherosclerosis, and AD-like conditions by counteracting -induced local and systemic inflammation, partly by inhibiting the accumulation of DNA aggregates, lipopolysaccharides (LPS), and gingipains in the gingival tissue, arterial wall, and brain. GV1001 attenuated the development of atherosclerosis by inhibiting vascular inflammation, lipid deposition in the arterial wall, endothelial to mesenchymal cell transition (EndMT), the expression of Cluster of Differentiation 47 (CD47) from arterial smooth muscle cells, and the formation of foam cells in mice with -induced periodontal disease. GV1001 also suppressed the accumulation of AD biomarkers in the brains of mice with periodontal disease. Overall, these findings suggest that GV1001 holds promise as a preventive agent in the development of atherosclerosis and AD-like conditions associated with periodontal disease.